Canada Clinical Diagnostics Market

1. A sample report on Canada Clinical Diagnostics Market Analysis

2. This report presents a strategic analysis of the Canada Clinical Diagnostics Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Canada Clinical Diagnostics Market, and offers unmatched value, accuracy, and expert insights.

3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

4. Table of Content CONTENT PG. NO. 12-25 1. Clinical Diagnostics Overview 1.1. Overview 1.2. Canada Overview 1.3. Economic Overview: Canada 1.4. Clinical Diagnostics Market in Canada 1.5. Healthcare Services Market in Canada 1.6. Healthcare Scenario in Canada 1.7. Health Insurance Coverage: Canada 1.8. Budget of the Government for Public Insurance 1.9. Mergers and Acquisitions 26-31 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 2.2. Market Segmentation 4 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

5. Table of Content CONTENT PG. NO. 2.2.1. By Test 2.2.2. By Product 2.2.3. By End User 32-37 3. Types of Clinical Diagnostics Test 3.1 Laboratory Test 3.2 Imaging Test 3.3 Molecular Diagnostics 3.4 Point-Of-Care Testing 38-42 4. Market Dynamics 4.1. Market Growth Drivers 4.1.1. Increasing Prevalence of Health Morbidities like Cancer, Chronic & Infectious Diseases 4.1.2. Growing awareness about early detection & screening of diseases 4.1.3. Government initiatives and investments in increasing number of equipment in diagnostic facility 5 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

6. Table of Content CONTENT PG. NO. 4.2. Market Restraints 4.2.1. Delayed in Diagnosis 4.2.2. Shortage of Diagnosis Equipment 43-53 4.2.3. Data Privacy Concerns 5. Competitive Landscape 5.1. Major Market Share 5.2. Key Company Profile 5.2.1. Dynacare 5.2.1.1. Overview 5.2.1.2. Product Applications & Services 5.2.1.3. Recent Developments 5.2.1.4. Partnerships Ecosystem 5.2.1.5. Financials (Based on Availability) 6 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

7. Table of Content CONTENT PG. NO. 5.2.2. LifeLabs Medical Laboratory Services 5.2.2.1. Overview 5.2.2.2. Product Applications & Services 5.2.2.3. Recent Developments 5.2.2.4. Partnerships Ecosystem 5.2.2.5. Financials (Based on Availability) 5.2.3. SickKids 5.2.3.1. Overview 5.2.3.2. Product Applications & Services 5.2.3.3. Recent Developments 5.2.3.4. Partnerships Ecosystem 5.2.3.5. Financials (Based on Availability) 5.2.4. MIC Medical Imaging 7 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

8. Table of Content CONTENT PG. NO. 5.2.4.1. Overview 5.2.4.2. Product Applications & Services 5.2.4.3. Recent Developments 5.2.4.4. Partnerships Ecosystem 5.2.4.5. Financials (Based on Availability) 5.2.5. Public Health Ontario 5.2.5.1. Overview 5.2.5.2. Product Applications & Services 5.2.5.3. Recent Developments 5.2.5.4. Partnerships Ecosystem 5.2.5.5. Financials (Based on Availability) 5.2.6. Biron 5.2.6.1. Overview 8 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

9. Table of Content CONTENT PG. NO. 5.2.6.2. Product Applications & Services 5.2.6.3. Recent Developments 5.2.6.4. Partnerships Ecosystem 5.2.6.5. Financials (Based on Availability) 5.2.7. Akumin Inc 5.2.7.1. Overview 5.2.7.2. Product Applications & Services 5.2.7.3. Recent Developments 5.2.7.4. Partnerships Ecosystem 5.2.7.5. Financials (Based on Availability) 5.2.8. AlphaLabs 5.2.8.1. Overview 9 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

10. Table of Content CONTENT PG. NO. 5.2.8.2. Product Applications & Services 5.2.8.3. Recent Developments 5.2.8.4. Partnerships Ecosystem 5.2.8.5. Financials (Based on Availability) 5.2.9. EFW Radiology 5.2.9.1. Overview 5.2.9.2. Product Applications & Services 5.2.9.3. Recent Developments 5.2.9.4. Partnerships Ecosystem 5.2.9.5. Financials (Based on Availability) 5.2.10. Spartan Bioscience: 5.2.10.1. Overview 10 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

11. Table of Content CONTENT PG. NO. 5.2.10.2. Product Applications & Services 5.2.10.3. Recent Developments 5.2.10.4. Partnerships Ecosystem 5.2.10.5. Financials (Based on Availability) 54-60 6. Reimbursement Scenario 6.1. Reimbursement Regulation 6.2. Reimbursement Process for Diagnosis 6.3 Reimbursement Process – Medicare 6.4 Reimbursement Process – Medicaid 61-67 7. Methodology & Scope 11 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

12. Canada Clinical Diagnostics Market Analysis 1. Clinical Diagnostics Overview

13. 1.1 Statistics at a Glance: Status of Clinical Diagnostics in the World Prevalence of Clinical Diagnostics Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ $76.2 Bn Was the market size of Global Clinical Diagnostics in 2022 8.56% Can be the exhibiting CAGR of the Clinical Diagnostics Market from 2022-2028 In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ 17-20% Is the expected increase in revenue of the diagnostic companies 55% Of the most downloaded clinically rated apps are linked to biosensors In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ $7 Bn/year Is the amount saved using the health apps by monitoring and diagnosing health condition associated with diabetes prevention and care, asthma, and cardiac and pulmonary rehabilitation 13 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

14. 1.1 Statistics at a Glance: The Status of Clinical Diagnostics in the World (continued) Europe ~Revenue to reach $xx Bn by 2027 Asia -Has the Fastest CAGR of xx % Canada Market ~$xx Mn North America ~ Market Size of $xx Bn Africa ~Market Size of $xx Bn Illustrative Illustrative 14 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

15. 1.2 Canada Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 38.45 Mn Is the population of Canada, in 2022 $1.99 Tn Is the Gross Domestic Product (GDP) in Canada in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 41 years Is the median age in Canada, in 2022 $8019 per capita was the amount of national health expenditures in 2021 15 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

16. 1.3 Economic Overview: Canada Population of Canada, (2020-2030) GDP of Canada, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 16 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

17. 1.4 Statistics at a Glance: Glance at Canada Clinical Diagnostics Market Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ $3.9 Bn Was the market size of Canada Clinical Diagnostics Market in 2022 3.1% Is the expected CAGR of the Canada Clinical Diagnostics Market for period of 2022- 2030 In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in Canada ▪ 7,307 Is the number of medical and diagnostic laboratory companies are present in Canada 50 to 82 days Is the average waiting period for CT scans in Canada In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 90% Is the rate of approval for the in-vitro diagnostics test application submitted for getting the diagnostic test done in Canada Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 17 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

18. 1.5 Healthcare Services in Canada Canada Healthcare Services Market Forecast, 2022-2030 (in $Bn) xx xx xx xx xx xx xx xx xx 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Healthcare Services market in Canada, which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 18 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

19. 1.6 Healthcare Scenario in Canada Clinical diagnostics Process: The process of developing a clinical diagnostics drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the clinical diagnostics drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating clinical diagnostics Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 19 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

20. 1.6 Healthcare Scenario: Diagnostic Process Patient Journey Patient sees family doctor or specialist Results get sent to pathologist/ radiologist for review and analysis Physician sends patient for medical imaging Patient Laboratory Test/Imaging Test/Molecular Diagnostic Next Step Based on the radiologist's report, the referring physician decides on the next steps for patient Pathologist/Radiologist Report contains summary of findings, possible diagnoses, and recommended next steps Pathologist/Radiologist produces a report and sends it to referring physician Physician 20 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

21. 1.7 Health Insurance Coverage: Canada Number of people with health insurance in Canada in 2020, by coverage type (in Mn) Number of People By Health Insurance Coverage (for illustrative purpose) 20 Accident & other Coverage Type 2020 2021 Change % 12 Disability Total 327,521 328,074 26 Supplementary Health Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 There are four main types of health insurance in Canada: Employment-based 178,737 178,285 –0.2 Public insurance Private local insurance International insurance Travel insurance ▪ ▪ ▪ ▪ Direct-purchase 33,869 33,555 –0.1 Marketplace coverage 10,924 11,389 0.1 Public insurance offers free healthcare. Eligibility and coverage differ among provinces. To be eligible for public insurance in Canada, you need to be physically present in Canada for over 183 days TRICARE 9,165 8,299 –0.3 Any public plan 112,925 117,095 1.2 Out of 37.5 Mn citizens, most are insured by the government, yet 25 Mn Canadians have opted for additional insurance Medicare 58,541 60,226 0.5 For public insurance, the cost of health insurance will be paid indirectly through your tax. On average, 10% of your income will go to public insurance Medicaid 58,778 61,940 0.9 VA and CHAMPVA 2,967 3,151 0.1 Local private insurance can cost around $100-$200 a month, while international insurance costs around $200-$300 a month Uninsured 28,291 27,187 –0.4 Illustrative Illustrative 21 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

22. 1.8 Budget of Canada Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Medicare In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Medicaid 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Medicare As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Medicaid National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 22 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

23. 1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 23 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

24. 1.9 Mergers and Acquisitions (continued) Latest Deals In Canada Company Key Insights In February 2023, The Clinical and Laboratory Standards Institute (CLSI) awarded PHO's laboratory the 2023 Excellence in Member Organization Leadership Award PHO assumed leading role in the Ontario COVID-19 Genomics Network and the COVID-19 Testing Strategy Expert Panel, in addition to participation in the COVID-19 Provincial Diagnostic Network in Ontario ▪ ▪ In December 2022, Biron Health Group's medical biology laboratory received a certification from the Standards Council of Canada for the ISO 15189 standard Medical labs - Requirements for quality and competence, after a conformity evaluation by the “Bureau de normalization du Québec” ▪ MIC has been an important provider of health care services in Northern Alberta, running 13 community-based imaging clinics and supplying contract services to 12 Edmonton area hospitals and community health centers In September 2021, PocketHealth, the creator of healthcare's most innovative digital image sharing solution, announced how MIC Medical Imaging opted its platform to make diagnostic image sharing more accessible for patients ▪ ▪ 24 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

25. 1.9 Mergers and Acquisitions (continued) Latest Deals In Canada Company Key Insights Merger details ▪ Merger Acquisition details ▪ Illustrative Illustrative 25 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

26. Canada Clinical Diagnostics Market Analysis 2. Market Size and Forecasting

27. 2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption Canada Clinical Diagnostics Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Malaysia, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Canada Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ % of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Canada Market Size (Bn $) 61 74 84 87 91 95 99 106 Illustrative Illustrative 27 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

28. 2.2 Snapshot of Clinical Diagnostics Market Segmentation By Test By Product By End-User Lipid Panel Instruments Hospital Laboratory Liver Panel Reagents Diagnostic Laboratory Renal Panel Others Point-of-care Testing Complete Blood Count Others Electrolyte Testing Infectious Disease Testing Others In this section you will get an understanding of the segmentations which will cover the Canada Clinical Diagnostics Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 28 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

29. 2.2.1 Market Segmentation: By Test Canada Clinical Diagnostics Market Share, By Test (2022) Lipid Panel market in Canada is a significant component of the overall clinical diagnostics treatment market ▪ Others Infectious Disease Testing It has the maximum market share in Canada clinical diagnostics market with approximately xx% ▪ Electrolyte Testing Lipid Panel Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Complete Blood Count In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Renal Panel Liver Panel Illustrative Illustrative 29 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

30. 2.2.2 Market Segmentation: By Product Canada Clinical Diagnostics Market Share, By Product (2022) Instruments clinical diagnostics market in Canada is a significant component of the overall clinical diagnostics market ▪ It has the maximum market share in Canada clinical diagnostics market with approximately xx% ▪ Others Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Instruments In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Reagents Illustrative Illustrative 30 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

31. 2.2.3 Market Segmentation: By End User Canada Clinical Diagnostics Market Share, By End User (2022) Hospital Laboratories have the maximum market share in Canada clinical diagnostics market with approximately xx% ▪ Others Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Point-of-care Testing In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Hospital Laboratory Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Diagnostic Laboratory Illustrative Illustrative 31 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

32. Canada Clinical Diagnostics Market Analysis 3. Types of Clinical Diagnostics Test

33. 3.1 Laboratory Test Top most commonly ordered laboratory tests in Canada Community Inpatient Emergency Complete blood count Chem panel 7 Complete blood count Electrolyte panel Complete blood count Creatinine Thyroid stimulating hormone Electrolyte panel Creatinine Magnesium Creatinine Electrolyte panel Alanine amino-transferase Hemoglobin A1c Phosphate Scan with morphology Liver panel Troponin-T LDL cholesterol Ferritin Urea Prothrombin time (INR) Prothrombin time (INR) Urinalysis with microscopic Urinalysis with microscopic Others Calcium Others Blood culture Others The data presented here includes over 51 commonly ordered laboratory tests by percentage in Canada (Appendix 3) 33 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

34. 3.2 Imaging Test Imaging tests in Canada include: X-rays, CT (Computed Tomography) scans, MRI (Magnetic Resonance Imaging) scans Ultrasound, PET (Positron Emission Tomography) scans, Nuclear imaging & Mammogram ▪ In 2022, it was estimated that 28,600 Canadian women will be diagnosed with breast cancer ultimately raising the demand for Mammography Imaging as well as services ▪ In August 2022, through a collaboration with Synthesis Health, Pelican Narrows and two additional Peter Ballantyne Cree Nation (PBCN) towns, Deschambault Lake and Southend, the first ultra portable X-ray equipment was installed in Canada ▪ Number of diagnostics expected to be performed in Canada (in Mn) Imaging Test 2017 2020 2030 Computed Tomography Scan (CT) in Mn XX XX XX Magnetic Resonance Imaging (MRI) in Mn XX XX XX Positron Emission Tomography (PET) in Mn XX XX XX 34 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

35. 3.3 Molecular Diagnostics Molecular diagnostic tests are laboratory tests that employ molecular biology techniques to detect particular genetic material (DNA or RNA) or protein or other molecule linked with a condition or disorder from the sample of tissue, blood, or other body fluids Molecular Diagnostic methods Molecular Diagnostics applications Oncology ( BRCA1, BRCA2, HER2, EGFR, KRAS) Polymerase chain reaction (PCR) Real-Time RT-PCR Infectious diseases (SARS-CoV-2,Flu A/B & RSV) Inherited genetic disorders (cystic fibrosis, sickle cell anaemia, down's syndrome and Huntington's disease) Next-generation sequencing (NGS) In-situ hybridization (ISH) Fluorescence In-Situ Hybridization (FISH) Disease progression monitoring Chromogenic in situ hybridization (CISH) Personalized medicine formulation Immunohistochemistry Reproductive Testing – Non-invasive Prenatal Tests (NIPT), IVF, New born screening Array-based comparative genomic hybridization 35 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

36. 3.4 Point-Of-Care Testing POC Diagnostics Market Share By Indication Key Insights Increased prevalence of diabetes and cancer, the use of novel point-of-care diagnostics, and the preference for at-home glucose testing all contribute to the expansion of the blood glucose monitoring market 8.9% of the population of Canada, or more than 3 Mn people, have diabetes, and after accounting for population ageing over time, the prevalence has been rising at an average rate of 3.3% each year Considerable risk of acquiring type 2 diabetes is also posed by the 6.1% prevalence of prediabetes in Canadian adults On the other side, the category for infectious disorders is expected to develop at the quickest rate Market segment for infectious diseases is anticipated to expand significantly over the forecast period due to the rising prevalence of various infectious disorders ▪ Hematology Testing Cardiometabolic Diseases ▪ Others Pregnancy & Infertility Testing ▪ Infectious Diseases ▪ Blood Glucose Monitoring ▪ Other*- Hyperthyroidism, Oxygen Testing, assessment for developing contrast- induced nephropathy (CIN), Colorectal cancer screening, Dipstick urinalysis 36 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

37. 3.4 Point-Of-Care Testing (continued) Community-based point-of-care testing policy (British Columbia) British Columbia Ministry of Health (the Ministry) regulates and influences the provision and utilization of POCT in particular medical/clinical domains through accreditation standards for diagnostic service providers and scope of practice regulations that specify which healthcare professionals are allowed to perform tests, interpret results, make diagnoses, and manage treatments. This is done to ensure the quality and safety of care in these settings Scope: This policy applies to This policy does not apply to Facilities that are health authority governed or subject to the CPSBC’s accreditation programs POCT provided as direct-to-consumer testing All community-based point-of-care settings where POCT is provided or deployed (e.g., a clinic, physician's office, pharmacy, or long-term care facility outside of a health authority) Virtual care settings (i.e., where an individual consults virtually with a health-care provider) POCT involving biologic specimens ▪ ▪ Test Settings ▪ ▪ POCT that does not involve the testing of biologic specimens (e.g., measurements using a blood pressure cuff, or instruments to measure weight, height, and temperature) Diagnostic imaging or screening services administered under the Medicare Protection Act ▪ ▪ Type of Testing ▪ Self-testing under guidance by a health-care provider at the time of testing (i.e., guided self-testing) Self-testing and direct-to-consumer testing ▪ ▪ Self-Testing 37 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

38. Canada Clinical Diagnostics Market Analysis 4. Market Dynamics

39. 4.1 Market growth drivers 3.1.1 Increasing Prevalence of Health Morbidities like Cancer, Chronic & Infectious Diseases. 44% of adults have at least 1 of 10 common chronic conditions in Canada Incidence of Diseases in Canada Incidence of diseases is increasing in Canada, with more than 1.8 Mn new clinical diagnostics cases expected to be diagnosed in 2023 ▪ This is driving the demand for clinical diagnostics treatments and creating opportunities for growth in the clinical diagnostics market ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 39 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

40. 4.1 Market growth drivers (continued) 3.1.2 Growing awareness about early detection & screening of diseases. The Canadian Task Force on Preventative Health Care recommends mammogram screening for women over the age of 50 Top countries that are leveraging technology in their fight against clinical diagnostics Canada has a long history of investing in clinical diagnostics research and treatment, and as a result, has become a world leader in the field ▪ Norway IT has a robust healthcare infrastructure, including world- renowned research institutions, hospitals, and clinics, that are dedicated to clinical diagnostics treatment and research ▪ Austria Denmark Belgium Spain One of the key factors that has allowed Canada to stay ahead in the field of clinical diagnostics research and treatment is the high level of investment in clinical diagnostics-related research ▪ Italy Netherlands Sweden Singapore Switzerland Israel In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Australia Canada France Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ United Kingdom China South Korea Germany Japan United States Illustrative Illustrative 40 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

41. 4.1 Market growth drivers (continued) 3.1.3 Government initiatives and investments in increasing number of equipment in diagnostic facility. Venture capital investment into health diagnostics companies peaked in 2020 with $4.8 Bn going into the sector. Since 2017, investors have infused nearly $20.3 Bn into this sector Fundings from government and other organizations Canada government provides significant support and funding for clinical diagnostics research and treatment, which is driving innovation and growth in the clinical diagnostics market ▪ Source Year Fund ($) National clinical diagnostics Institute (NCI) 2021 $ 6.4 Bn Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Centers for Disease Control and Prevention (CDC) In order to obtain access to all of the information that you are seeking, you will need to purchase the final report 2021 $ 501 Mn ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ American clinical diagnostics Society (ACS) 2020 $ 150 Mn Susan G. Komen 2020 $ 98 Mn Illustrative Illustrative 41 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

42. 4.2 Market restraints 3.2.3 Data Privacy Concerns. More than 400 hospitals in Canada and the US have been subject to ransomware attacks since the beginning of the pandemic 3.2.1 Delayed in Diagnosis. 61.6% of Canadians with a mood and/or anxiety disorder had their diagnosis more than a year after symptom onset 3.2.2 Shortage of Diagnosis Equipment. 35.5% of Canadian Medical Imaging equipment is 10 or more years old There is a shortage of oncologists in Canada, which can limit access to clinical diagnostics treatments and create barriers to growth in the clinical diagnostics market Clinical diagnostics treatments can be very expensive and can lead to financial burden for patients and healthcare systems ▪ ▪ Requirements for clinical diagnostics treatments can be very stringent, which can slow down the approval process and limit access to new treatments ▪ Cost of clinical diagnostics treatment varies depending on the type of clinical diagnostics, stage of clinical diagnostics, and treatment options ▪ Oncologists are physicians who specialize in the diagnosis and treatment of clinical diagnostics ▪ Regulatory bodies, such as Canada Food and Drug Administration (FDA), require extensive clinical trials and safety data before approving new clinical diagnostics treatments ▪ With the aging population and the increasing incidence of clinical diagnostics, there is a growing demand for oncologists ▪ Some common clinical diagnostics treatments, such as chemotherapy and radiation therapy, can cost tens of thousands of dollars ▪ This can be a lengthy and costly process, which can delay the availability of new treatments for patients ▪ However, the supply of oncologists is not keeping pace with the demand Illustrative Illustrative ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. 42 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

43. Canada Clinical Diagnostics Market Analysis 5. Competitive Landscape

44. 5.1 Major Market Share Revenue of Major players in Canada clinical diagnostics Market ($ Mn) Canada clinical diagnostics market is a highly competitive space, with many companies developing and marketing clinical diagnostics treatments ▪ Other Some of the top companies in Canada clinical diagnostics market based on revenue and market share include ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ XX Illustrative Illustrative 44 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

45. 5.2 Key Company Profile Key Note: 1 Dynacare Here is the list of top 10 companies which will cover in the final report ▪ LifeLabs Medical Laboratory Services 2 Each company will have slides for ▪ 3 Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report SickKids o o 4 MIC Medical Imaging o o 5 Public Health Ontario o 6 o Biron o 7 Akumin Inc o 8 AlphaLabs ▪ 9 EFW Radiology ▪ 10 Spartan Bioscience: 45 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

46. 5.2.1 Dynacare Solutions offered by Dynacare ▪ Dynacare provides a comprehensive variety of laboratory testing services ▪ It includes regular and specialized tests in hematology, clinical chemistry, immunology, and genetics ▪ It has over 165 patient care centers across Quebec, Ontario, Manitoba, Alberta and British Columbia in Canada ▪ Company is owned by Lab Corp, an American company based out of Burlington, North Carolina Founded in: 1959 ➢ Diagnostics HQ: Ontario, Canada ➢ Community Solutions Type: Private Revenue: $977.9 Mn ➢ Hospital Solutions Website: www.dynacare.ca ➢ Dynacare Logistics Services Offered Recent Activity / Press Coverage Prenatal Tests HPV Testing The Brampton Board of Trade is delighted to announce that Vito Ciciretto, President & CEO of Dynacare, has been named 2021 Brampton Business Person of the Year. Pharmacogenomic Tests Allergy Testing Pharmacogenomic Tests Cervical Cancer/HPV Testing Dynacare, a Labcorp subsidiary and one of Canada’s leading health and wellness solutions providers, today announced that they have entered into an agreement to acquire Valley Medical Laboratories in British Columbia effective May 1, 2023. QuantiFERON®-TB Testing Hereditary Cancer Screening Pap Test Heart Health 46 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

47. 5.2.1 Dynacare (continued) Partnerships Ecosystem Major Companies Major Partners ▪ Central Medical Laboratories (CML) is established in Winnipeg, Manitoba. ▪ LabCorp had acquired Dynacare Laboratories, becoming the majority shareholder of Gamma-Dynacare Medical Laboratories ▪ CML continues to operate as an important division in the Dynacare group of companies ▪ Dynacare took a strategic move by introducing a new national healthcare logistics business - Accuro Health Services ▪ Bio-Science Laboratory, now part of the Dynacare Medical Laboratories partnership ▪ Dynacare acquires Lab Bio-Médic, a privately owned laboratory in Quebec that provides services to medical clinics, industries, insurance companies and clinical research organizations ▪ Gamma-Dynacare Medical Laboratories created by a partnership between Dynacare, Gamma North Peel Partnership and Bio-Science Laboratory 47 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

48. 5.2.1 Dynacare (continued) Important Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Dynacare, a Labcorp subsidiary announced that they have entered into an agreement to acquire Valley Medical Laboratories in British Columbia The combined strength of Dynacare and Valley Medical will offer an expansive patient service centre network and diagnostic test menu to patients, customers, and the healthcare community ▪ Acquisition - May, 2023 ▪ LabCorp acquired all of the outstanding shares of Dynacare and financed the transaction ▪ The first national clinical laboratory to fully embrace genomic testing, Laboratory Corporation of America(R) Holdings (LabCorp(R)) has been a pioneer in commercializing new diagnostic technologies ▪ Acquisition $488 Mn July 2002 48 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

49. 5.2.1 Dynacare (continued) Revenues ($Bn), 2020-2030 $977.9 Mn was the revenue generated by Dynacare in 2022 ▪ They are profitable in a wide range of laboratory testing services including routine and specialty tests in areas such as hematology, clinical chemistry, immunology, molecular diagnostics and genetics ▪ 70.9 70.3 63.3 Revenue generated by Dynacare in 2020 reflects the company's continued growth and success in the healthcare industry ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2022 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 1 2 3 4 Illustrative Illustrative 49 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential

50. 5.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for clinical diagnostics Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 50 A Sample Report on Canada Clinical Diagnostics Market Analysis I Confidential